Valneva reports Q3 results; reaffirms FY22 guidance

Nov. 10, 2022 3:53 AM ETValneva SE (VALN), INRLF, VNVLFBy: Meghavi Singh, SA News Editor1 Comment
  • Valneva press release (NASDAQ:VALN): Q3 Cash and cash equivalents of €261.0M at the end of September 2022
  • Revenue of €249.9M (+258.0% Y/Y).
  • Valneva reiterates expected total revenues of €340 million to €360 million. 
  • Product sales of the Company’s travel vaccines are still expected to reach €70 million to €80 million despite supply challenges and COVID-19 product sales are expected to reach €30 million to €40 million. Other Revenues are expected to reach approximately €240 million.
  • Valneva now expects lower R&D expenses of €95 million to €110 million compared to the €120 million to €135 million previously communicated. 

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.